BioCryst wins ap­proval for HAE pill and charges half-a-mil­lion dol­lars, but will any­one take it?

Six years af­ter the FDA OK’d their flu an­tivi­ral peramivir, BioCryst has notched an­oth­er ap­proval.

The North Car­oli­na-based biotech an­nounced Thurs­day that the FDA had ap­proved bero­tral­stat, a dai­ly pill meant to pre­vent painful episodes in pa­tients with the rare dis­ease hered­i­tary an­giode­ma (HAE). The mol­e­cule, which Biocryst has been study­ing in the clin­ic since 2013, will be sold un­der the name Or­ladeyo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER